logo
  

Primerica Counters Misleading Blog, Defends Integrity Of Business Operations

Primerica Inc. (PRI), a financial services provider across the United States and Canada, has responded to a recent blog post containing false claims aimed at lowering the company's stock price.

The company asserts that the blog's assertions misrepresent Primerica's commitment to assisting middle-income families through its licensed sales force.

Primerica views the blog as a self-serving attempt to manipulate stock prices to the detriment of its shareholders.

For more than 47 years, Primerica has provided financial products and services to households in the United States and Canada. The company protect over 5.7 million lives with life insurance and paid over $1.8 billion in claims to the families of
clients last year. It also has 2.9 million clients who trust the company with almost
$100 billion of investments, Primerica said in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement major Lowe's Companies, Inc. on Tuesday maintained its fiscal 2024 earnings and sales outlook after reporting weak results in its first quarter. However, the quarterly earnings per share were above market estimates. In pre-market activity on the NYSE, Lowe's shares were gaining around 3.1 percent... Veolia (VE) announced Tuesday that its consulting engineering and strategic and operational assistance division Seureca announced the acquisition of MRC Consultants and Transaction Advisers. The financial aspects of the deal are not revealed. The combination of MRC, an energy consulting firm in Spain... French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT